OOIR: Observatory of International Research

Papers

(The H4-Index of Gynecologic Oncology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer	196
Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency	126
Association between time to adjuvant chemotherapy and outcomes in low grade ovarian cancer	89
Innovations in surgery and peri-operative care: A technical gimmick or true oncology advance?	85
Platinum resistance: The great prognostic equalizer? Association between early disease characteristics and survival after diagnosis of platinum resistance in ovarian cancer	81
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	78
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	75
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis	69
Impact of the 2023 FIGO staging on a high-risk endometrial cancer cohort	67
Evaluating nutrition in advanced ovarian cancer: Which biomarker works best?	66
Clinical characteristics of ovarian cancer patients with pathologic complete response after neoadjuvant chemotherapy	66
Barriers faced by obstetrics and gynecology providers and trainees in providing HPV vaccination to patients aged 27–45 years	63
Variables impacting postoperative length of stay for gynecologic cancer patients in the era of same day minimally invasive hysterectomy	61
Economic burden of cervical cancer in Latin America: A real-world study	61
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	61
The outcome of waiting for radiotherapy in locally advanced cervical cancer	60
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	55
Fertility-sparing surgery versus standard surgery for early-stage cervical cancer: Five-year life expectancies by tumor size	52
Chemoradiotherapy response and the tumor microenvironment in a novel immunocompetent mouse model of cervical cancer	51
Assessment of endocrine toxicities among gynecologic oncology patients receiving immunotherapy	49
Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with	49
Successful implementation of a goals-to-discharge patient checklist following surgery for gynecologic cancer	48
RE1 transcription factor is decreased in endometrial cancer	48
A phase II, two-stage study of avelumab and axitinib among patients with mismatch repair proficient recurrent or persistent endometrial cancer: Final efficacy analysis and correlative studies	47
Factors associated with human papillomavirus vaccination: Determining the effect of implicit and explicit racial bias and state laws around vaccination	47

A randomized controlled trial of wound infiltration with liposomal bupivacaine with or without intrathecal analgesia in patients undergoing laparotomy for advanced gynecologic malignancy	47
Population-based BRCA1 and BRCA2 genetic testing is cost-effective in Canada	46
Focal adhesion kinase inhibitors as maintenance therapy in a homologous recombination repair proficient high-grade serous ovarian cancer murine model	46
The prognostic value of circulating minimal residual disease in first-line treatment of ovarian cancer	45
Endometrial pathology among premenopausal patients seeking emergency care for abnormal uterine bleeding: High risk of endometrial malignancy and premalignancy	43
Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma	43
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	43
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab among patients with recurrent endometrial cancer	42
The effect of Medicaid expansion on the receipt of guideline-concordant care among patients with cervical cancer in the United States: A difference-in-difference analysis of the National Cancer Databa	42
Impact of geographic region of birth on overall survival among Hispanic women with endometrial cancer	42
BRCA and homologous recombination repair deficiency testing in advanced ovarian cancer: A real-world data analysis	41
Language as a barrier to clinical trial enrollment: Identifying methods to improve clinical trial enrollment in minority and non-English-speaking patients	40
A phase II study evaluating carboplatin/paclitaxel/pembrolizumab among newly diagnosed stage III/IV epithelial ovarian cancer patients receiving neoadjuvant chemotherapy followed by olaparib/pembroliz	40
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	40
PDE1A in epithelial ovarian cancer: Oncogenic role, metastatic association, and potential as a prognostic biomarker and therapeutic target	39